4.8 Editorial Material

Harnessing Nanomedicine for Mucosal Theranostics-A Silver Bullet at Last?

Journal

ACS NANO
Volume 7, Issue 4, Pages 2883-2890

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/nn400885b

Keywords

-

Ask authors/readers for more resources

Inflammatory bowel disease (IBD) has been extensively studied in the last four decades both in animal models and humans. The treatment options remain disappointing, nonspecific, and associated with multiple systemic adverse effects. In this Perspective, we highlight issues related to emerging nanotechnologies designed particularly for treatment and disease management of IBD and discuss potential therapeutic target options with novel molecular imaging modalities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Endocrinology & Metabolism

Time-limited diets and the gut microbiota in cardiometabolic disease

Karina Ratiner, Hagit Shapiro, Kim Goldenberg, Eran Elinav

Summary: Intermittent fasting is considered a promising treatment for cardiometabolic diseases and has positive effects on the gut microbiome and the host circadian clock. This review discusses the relationship between gut microbiome alterations and intermittent fasting's impact on mammalian metabolism and cardiovascular diseases, highlighting the challenges of linking bacterial signals with dietary cues and incorporating microbiome into precision medicine.

JOURNAL OF DIABETES (2022)

Review Physiology

Engineering bacteria to modulate host metabolism

Dragos Ciocan, Eran Elinav

Summary: The gut microbiota, composed of various microorganisms, has a significant impact on host metabolism and disease development. It can either have harmful effects or provide benefits to the host. Recently, therapeutic strategies targeting the gut microbiota, such as the use of engineered bacteria, have been developed to modulate the microbiota for the treatment of metabolic disorders.

ACTA PHYSIOLOGICA (2023)

Editorial Material Nutrition & Dietetics

Diversifying nutritional sciences-dietary practices and gut bacteria in individuals of Latino and Hispanic ancestry

Avner Leshem, Eran Elinav

AMERICAN JOURNAL OF CLINICAL NUTRITION (2023)

Review Microbiology

Impact of caloric restriction on the gut microbiota

Lara Kern, Denise Kviatcovsky, Yiming He, Eran Elinav

Summary: The impact of restrictive diets on gut microbiota composition and function, as well as their overall influences on host health and disease risk, are discussed. The evidence of long-term efficacy, adverse effects, and mechanisms of activity of caloric restriction and related diets is currently incomplete.

CURRENT OPINION IN MICROBIOLOGY (2023)

Review Gastroenterology & Hepatology

Fungi and cancer

Aurelia Saftien, Jens Puschhof, Eran Elinav

Summary: This review highlights the potential role of commensal and pathogenic fungi in modulating cancer-related processes and explores the mechanisms by which fungi influence tumor biology. It discusses the prospects of using fungi-related molecular signatures in cancer diagnosis, patient stratification, and assessment of treatment responsiveness. The review also emphasizes the challenges and limitations in conducting such research. Overall, it demonstrates that fungi likely play significant roles in mucosal and tumor-residing microbiomes and suggests the potential utilization of fungal inter-kingdom interactions in cancer diagnosis and treatment.
Article Chemistry, Multidisciplinary

Targeted nanomedicine: Lessons learned and future directions

Nuphar Veiga, Yael Diesendruck, Dan Peer

Summary: Designing a therapeutic modality with specific delivery to certain organs, tissues, or cell types is essential for efficient treatment and minimizing off-target side effects. Nanoparticles loaded with various drugs have emerged as a promising approach to achieve this goal. However, successful targeted delivery requires overcoming multiple biological barriers, such as systemic distribution, tissue penetration, and intracellular trafficking. Recent advances in understanding these barriers and functionalizing nanoparticles with targeting moieties have shown tremendous progress. Implementing new approaches like multi-functionalized nanocarriers and machine learning models can further enhance the design of safe and cell-specific nanoparticle delivery systems. This review critically examines the current progress in the field and proposes novel strategies to improve cell-specific delivery of therapeutic payloads.

JOURNAL OF CONTROLLED RELEASE (2023)

Editorial Material Biotechnology & Applied Microbiology

Drug delivery research and much more: interview with Dan Peer

Dan Peer

NANOMEDICINE (2023)

Editorial Material Biotechnology & Applied Microbiology

CRISPR editing in the lung with novel lipids

Uri Elia, Edo Kon, Dan Peer

Summary: Improved lipid nanoparticles are used to deliver CRISPR RNA to the mouse lung via inhalation.

NATURE BIOTECHNOLOGY (2023)

Editorial Material Biochemistry & Molecular Biology

Human microbiome research: Growing pains and future promises

Jens Puschhof, Eran Elinav

Summary: Human microbiome research is transitioning from association-based studies to understanding the effects of active strains on the human body. Despite challenges, progress has been made in utilizing data-driven microbiome diagnostics and interventions, potentially leading to breakthroughs in precision medicine in the next decade.

PLOS BIOLOGY (2023)

Article Engineering, Biomedical

Genome editing in cancer: Challenges and potential opportunities

Dor Breier, Dan Peer

Summary: Since its discovery in 2012, the CRISPR/Cas9 system has revolutionized genome editing and shown potential as a therapy for genetic diseases and cancer. However, there are challenges to be addressed before clinical testing, including the safety of in-vivo therapies and effects on genomic stability.

BIOACTIVE MATERIALS (2023)

Article Nanoscience & Nanotechnology

Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium

Joke Deprez, Rein Verbeke, Sofie Meulewaeter, Ilke Aernout, Heleen Dewitte, Tine Decruy, Julie Coudenys, Julie Van Duyse, Gert Van Isterdael, Dan Peer, Roy van der Meel, Stefaan C. C. De Smedt, Peggy Jacques, Dirk Elewaut, Ine Lentacker

Summary: The therapeutic potential of liposomes for drug delivery to inflamed tissue is well-established. The main mechanism of liposomal transport into inflamed joints is believed to be selective extravasation through endothelial gaps at inflammatory sites, known as the enhanced permeation and retention effect. However, the role of blood-circulating myeloid cells in liposome uptake and delivery has been largely overlooked. A study using a collagen-induced arthritis model demonstrates that myeloid cells can transport liposomes to inflammatory sites, and their depletion significantly reduces liposomal accumulation. Contrary to the prevailing theory, the long circulation times of PEGylated liposomes actually favor uptake by myeloid cells, challenging the current understanding of synovial liposomal accumulation and highlighting the potential for alternative delivery pathways in inflammatory diseases.

NATURE NANOTECHNOLOGY (2023)

Review Oncology

Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects

Edo Kon, Nitay Ad-El, Inbal Hazan-Halevy, Lior Stotsky-Oterin, Dan Peer

Summary: In oncology, mRNA-lipid nanoparticles (LNPs) have been used either to achieve intratumoural expression of immune-stimulating cytokine combinations or as cancer vaccines, and new strategies are in development to enable the selective delivery of payloads into cancer cells previously considered unreachable. The authors of this Review present various approaches for delivering mRNA-LNPs to tumours and discuss improvements that will improve the selective targeting of cancer cells with mRNA-LNPs.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Article Biotechnology & Applied Microbiology

Ex vivo intestinal permeability assay (X-IPA) for tracking barrier function dynamics

Hadar Bootz-Maoz, Ariel Simon, Sara Del Mare-Roumani, Yifat Bennet, Einat Toister, Hadar Romano, Danping Zheng, Sivan Amidror, Eran Elinav, Nissan Yissachar

Summary: In this study, the researchers developed an ex vivo intestinal permeability assay, X-IPA, for quantitative analysis of gut permeability dynamics. They found that specific gut microbes and metabolites can rapidly and dose-dependently increase gut permeability, providing a powerful tool for investigating barrier functions.

NPJ BIOFILMS AND MICROBIOMES (2023)

Review Biotechnology & Applied Microbiology

Intracellular bacteria in cancer-prospects and debates

Lena Schorr, Marius Mathies, Eran Elinav, Jens Puschhof

Summary: Recent evidence suggests that some human cancers may contain low-biomass microbial ecosystems, including bacteria, viruses, and fungi. Bacteria, being the most studied group, are found to localize within cancer cells, immune cells, and other tumor microenvironment cell types, potentially impacting various cancer-related functions. By integrating sequencing-based and spatial techniques, the identification of bacterial tumor niches is made possible. However, proving the existence and function of intratumoral microbes in cancer remains a challenge.

NPJ BIOFILMS AND MICROBIOMES (2023)

Review Oncology

CAR-T Cell Therapy and the Gut Microbiota

Sahana Asokan, Nyssa Cullin, Christoph K. Stein-Thoeringer, Eran Elinav

CANCERS (2023)

No Data Available